The effect of dofetilide on ventricular defibrillation thresholds

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 1, 2009, Pages 24-28

  Simon, Ron D B ^a   Sturdivant, J Lacy ^a   Leman, Robert B ^a   Wharton, J Marcus ^a   Gold, Michael R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dofetilide; Increasing safety margin; Reducing high defibrillation thresholds

Indexed keywords

AMIODARONE; DOFETILIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONVULSIVE THERAPY; DEFIBRILLATION THRESHOLD; DEFIBRILLATOR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HUMAN; MALE;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; SULFONAMIDES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION;

EID: 58149196565     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02172.x     Document Type: Article

References (24)

1. Raitt MH, Johnson G, Dolack GL, Poole JE, Kudenchuk PJ, Bardy GH. Clinical predictors of the defibrillation threshold with the unipolar implantable defibrillation system. J Am Coll Cardiol 1995 25 : 1576 1583.
2. Hodgson DM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol 2002 25 (4 Pt 1 408 413.
3. Merkely B, Lubinski A, Kiss O, Horkay F, Lewicka-Nowak E, Kempa M, Szabolcs Z, et al. Shortening the second phase duration of biphasic shocks: Effects of class III antiarrhythmic drugs on defibrillation efficacy in humans. J Cardiovasc Electrophysiol 2001 12 : 824 827.
4. Mouchawar G, Kroll M, Val-Mejias JE, Schwartzman D, McKenzie J, Fitzgerald D, Prater S, et al. ICD waveform optimization: A randomized, prospective, pair-sampled multicenter study. Pacing Clin Electrophysiol 2000 23 (11 Pt 2 1992 1995.
5. Shorofsky SR, Gold MR. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol 1996 78 : 313 316.
6. Mainigi SK, Callans DJ. How to manage the patient with a high defibrillation threshold. Heart Rhythm 2006 3 : 492 495.
7. Gradaus R, Block M, Seidl K, Brunn J, Isgro F, Hammel D, Hauer B, et al. Defibrillation efficacy comparing a subcutaneous array electrode versus an "active can" implantable cardioverter defibrillator and a subcutaneous array electrode in addition to an "active can" implantable cardioverter defibrillator: Results from active can versus array trials I and II. J Cardiovasc Electrophysiol 2001 12 : 921 927.
8. Lenz TL, Hilleman DE. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc) 2000 36 : 759 771.
9. Hilleman DE, Bauman AL. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review. Pharmacotherapy 2001 21 : 556 575.
10. Mehdirad AA, Carnes CA, Nelson SD. The influence of specific and nonspecific potassium current blockade on the defibrillation energy requirement of biphasic shock. Pacing Clin Electrophysiol 1999 22 (1 Pt 2 147 151.
11. Murakawa Y, Yamashita T, Kanese Y, Omata M. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms? Pacing Clin Electrophysiol 1998 21 : 1901 1908.
12. Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol 1997 30 : 233 236.
13. Guanzon AV, Crouch MA. Phase IV trial evaluating the effectiveness and safety of dofetilide. Ann Pharmacother 2004 38 : 1142 1147.
14. Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, et al. A multicentre, double-blind randomised crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001 22 : 2180 2191.
15. Page RL. Effects of antiarrhythmic medications on implantable cardioverter-defibrillator function. Am J Cardiol 2000 85 : 1481 1485.
16. Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk MM, Peters RW, Gold MR. Temporal decline in defibrillation thresholds with an active pectoral lead system. J Am Coll Cardiol 2001 38 : 1150 1155.
17. Olsovsky MR, Pelini MA, Shorofsky SR, Gold MR. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol 1998 9 : 240 244.
18. Poole JE, Bardy GH, Dolack GL, Kudenchuk PJ, Anderson J, Johnson G. Serial defibrillation threshold measures in man: A prospective controlled study. J Cardiovasc Electrophysiol 1995 6 : 19 25.
19. Hohnloser SH, Dorain P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: The optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006 114 : 104 109.
20. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, Payne J, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: Primary results from the Low Energy Safety Study (LESS). Circulation 2002 105 : 2043 2048.
21. Shorofsky SR, Peters RW, Rashba EJ, Gold MR. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol 2004 27 : 218 220.
22. Pelosi F, Oral H, Kim MH, Sticherling C, Horwood I, Knight BP, Michaud GF, et al. Effects of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000 11 : 736 740.
23. Dillon SM. Optical recordings in the rabbit heart show that defibrillation strength shocks prolong the duration of depolarization and the refractory period. Circ Res 1991 69 : 842 856.
24. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993 72 : 72A 79A.